<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65964">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247128</url>
  </required_header>
  <id_info>
    <org_study_id>POPTAV005</org_study_id>
    <nct_id>NCT02247128</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>POPular-TAVI</acronym>
  <official_title>Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, a variety of antithrombotic regimens are prescribed in the early postprocedure
      period after transcatheter aortic valve implantation (TAVI). Dual antiplatelet therapy
      (DAPT) using aspirin and a thienopyridine in the initial period after TAVI is the
      recommended strategy; however, mono antiplatelet therapy using aspirin is suggested not to
      be inferior. In patients with atrial fibrillation (AF) or another indication for oral
      anticoagulation (OAC), no recommendations on best treatment regimen currently exist although
      triple therapy (OAC + DAPT) is best avoided due to increased bleeding risk.

      We hypothesise that the omission of clopidogrel in the first 3 months after TAVI is safer
      and not less beneficial than the addition of clopidogrel to aspirin (cohort A) or OAC
      (cohort B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of two cohorts:

        -  Cohort A, patients without an indication for OAC prior to TAVI.

        -  Cohort B, patients with an indication for OAC prior to TAVI (eg. atrial fibrillation,
           mechanic mitral valve prosthesis).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome is a safety endpoint, defined as freedom of all bleeding complications at 1 year after TAVI. The co-primary outcome is the safety endpoint defined as freedom of non-procedure related bleeding complications at 1 year after TAVI. For the classification of bleeding complications the Bleeding Academic Research Consortium Definition for Bleeding (BARC) bleeding classification is primarily used according to the Valve Academic Research Consortium (VARC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net-clinical benefit endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>The secondary outcome is a net-clinical benefit endpoint, defined as freedom of the non-hierarchical composite of cardiovascular mortality, non-procedure related bleeding, stroke, or myocardial infarction at 1 year after TAVI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>The co-secondary outcome is an efficacy endpoint, defined as freedom of the non-hierarchical composite of cardiovascular mortality, ischemic stroke, or myocardial infarction at 1 year after TAVI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacoeconomics endpoint</measure>
    <time_frame>1 year</time_frame>
    <description>Outcome measure is quality-adjusted life years</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Stroke</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Aspirin + Clopicogrel (Cohort A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin monotherapy (Cohort A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAC + Clopicogrel (Cohort B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAC monotherapy (Cohort B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin + clopidogrel</intervention_name>
    <arm_group_label>Aspirin + Clopicogrel (Cohort A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin monotherapy</intervention_name>
    <arm_group_label>Aspirin monotherapy (Cohort A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAC + clopicogrel</intervention_name>
    <arm_group_label>OAC + Clopicogrel (Cohort B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAC monotherapy</intervention_name>
    <arm_group_label>OAC monotherapy (Cohort B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort A

             1. Patient has provided written informed consent.

          -  Cohort B

               1. Need for long-term oral anticoagulation;

               2. Patient has provided written informed consent.

        Exclusion Criteria:

          -  Cohort A

               1. Need for long-term oral anticoagulation;

               2. Drug-eluting stent implantation within 3 months prior to TAVI procedure;

               3. Bare-metal stent implantation within 1 month prior to TAVI procedure;

               4. Allergy or intolerance to aspirin or clopidogrel.

          -  Cohort B

               1. Drug-eluting stent implantation within 3 months prior to TAVI procedure;

               2. Bare-metal stent implantation within 1 month prior to TAVI procedure;

               3. Use of non-vitamin K oral anticoagulation (NOAC);

               4. Allergy or intolerance to OAC or clopidogrel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurrien M ten Berg, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pieter R Stella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht (UMCU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jurrien M ten Berg, MD, PhD</last_name>
    <phone>+31 88 320 1121</phone>
    <email>j.ten.berg@antoniusziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent J Nijenhuis, MD</last_name>
    <phone>+31 88 320 1121</phone>
    <email>v.nijenhuis@antoniusziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <state>Brabant</state>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter den Heijer, MD, PhD</last_name>
      <phone>+31 76 595 5000</phone>
      <email>PdHeyer@Amphia.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guus Brueren, MD, PhD</last_name>
      <phone>+31 40 239 9111</phone>
      <email>guus.brueren@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Kievit, MD, PhD</last_name>
      <phone>+31 24 361 1111</phone>
      <email>Peter.Kievit@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Baan, MD, PhD</last_name>
      <phone>+31 20 566 9111</phone>
      <email>j.baan@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stichting Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>van Houwelingen, MD</last_name>
      <email>K.vanHouwelingen@mst.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnoud WJ van 't Hof, MD, PhD</last_name>
      <phone>+31 38 424 5000</phone>
      <email>a.w.j.vant.hof@isala.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurrien M ten Berg, MD, PhD</last_name>
      <phone>+31 88 320 1121</phone>
      <email>j.ten.berg@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Jurrien M ten Berg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent J Nijenhuis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ad FM van den Heuvel, MD, PhD</last_name>
      <phone>+31 50 361 6161</phone>
      <email>a.f.m.van.den.heuvel@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leo Veenstra, MD</last_name>
      <phone>+31 43 387 6543</phone>
      <email>l.veenstra@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter R Stella, MD, PhD</last_name>
      <phone>+31 88 755 5555</phone>
      <email>p.stella@umcutrecht.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 10, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Implantation (TAVI)</keyword>
  <keyword>Transcatheter Aortic Valve Replacement (TAVR)</keyword>
  <keyword>Aortic Valve Disease</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Ischemic stroke</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Embolism and Thrombosis</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Antithrombotic treatment</keyword>
  <keyword>Oral anticoagulation</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Genetic Testing</keyword>
  <keyword>Cytochrome P450 2C19 (CYP2C19)</keyword>
  <keyword>Prostaglandin-endoperoxide synthase 2(PTGS2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
